Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Oramed Pharmaceuticals (ORMP) Shares Issued (2016 - 2025)

Oramed Pharmaceuticals filings provide 15 years of Shares Issued readings, the most recent being $500000.0 for Q1 2025.

Quarterly Shares Issued changed N/A to $500000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $500000.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $2.4 million for FY2023, 1511.09% up from the prior year.
Shares Issued hit $500000.0 in Q1 2025 for Oramed Pharmaceuticals, up from -$2000.0 in the prior quarter.
Across five years, Shares Issued topped out at $80.0 million in Q3 2021 and bottomed at -$2.9 million in Q3 2022.
Average Shares Issued over 4 years is $9.1 million, with a median of $2.4 million recorded in 2023.
The largest annual shift saw Shares Issued soared 1711.77% in 2021 before it decreased 18.15% in 2023.
Oramed Pharmaceuticals' Shares Issued stood at $10.6 million in 2021, then plummeted by 99.81% to $20000.0 in 2022, then plummeted by 110.0% to -$2000.0 in 2023, then surged by 25100.0% to $500000.0 in 2025.
Per Business Quant, the three most recent readings for ORMP's Shares Issued are $500000.0 (Q1 2025), -$2000.0 (Q3 2023), and $2.4 million (Q1 2023).